• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools


Patient Care spoke with renowned cardiologist Dr Mikhail Kosiborod and widely-recognized family physician Dr Neil Skolnik, about the expanded indications for sodium-glucose cotransporter-2 (SGLT2) inhibitors and how their availbility creates the perfect opportunity to broaden the scope of type 2 diabetes (T2D) management, with treatment goals that target a patient's full cardiometabolic profile, not elevated blood glucose alone.

In this final part of the conversation Kosiborod and Skolnik each highlight 3 thoughts for primary care clinicians to keep in mind that will help broaden their view of caring for their patients with T2D.

For more of the conversation with Drs Kosiborod and Skolnik, please see:

Mikhail Kosiborod, MD, is professor of medicine, University of Missouri Kansas City, vice president, Research, Saint Luke’s Health System, executive director, Cardiometabolic Center Alliance, Director, Cardiometabolic Research and codirector, Haverty Cardiometabolic Center of Excellence, Saint Luke’s Mid America Heart Institute, Kansas City, MO.

Neil Skolnik, MD, is professor of family and community medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.